New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
Approval strengthens the company’s growing international anti-infective portfolio
The deal, backed by healthcare investor ARCHIMED, signals a major push to accelerate connected, patient-centered cardiac care worldwide
Backed by ARCHIMED, the deal strengthens connected cardiac diagnostics with integrated Holter, ABPM, and telemedicine solutions
Growth was broad-based across segments
Arcot is a seasoned executive with more than two decades of experience across the global pharma and life sciences sectors
Subscribe To Our Newsletter & Stay Updated
